Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 12;12:667515. doi: 10.3389/fimmu.2021.667515

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Pleguezuelo, Díaz-Simón, Cabrera-Marante, Lalueza, Paz-Artal, Lumbreras and Serrano Hernández

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Change in aPL levels before and after therapy. An extreme drop in aPL levels lasting for 4 days was observed after two sessions of plasmapheresis. aPS/PT IgM values even rose to higher levels than in baseline after plasmapheresis. One week after the first dose of daratumumab was administered, aCL IgG and aB2GPI IgG started a decline, this decline lasting until day +108. After day +108, a significant climb began. Levels of aPS/PT IgG lowered until day +248 and then went up again. Levels of aPS/PT IgM showed an intermittent up and down profile, but they have remained stable at half the titer of baseline from day +189 and onwards. PE, plasmapheresis; DARA, daratumumab.